Lilly, Merck announce another immuno-oncology collaboration

[News]

Eli Lilly and Company and Merck, known as MSD outside the United States and Canada, today announced another immuno-oncology collaboration that will evaluate abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, and Merck's KEYTRUDA (pembrolizumab) in a Phase I study across multiple tumor types.

More... (http://www.news-medical.net/news/20151210/Lilly-Merck-announce-another-immuno-oncology-collaboration.aspx)